Simultaneous automated and continuous monitoring of glucose and lactate in cell cultures
C-CIT Sensors launches its innovative and easy-to-handle single-use wireless bi-parametric metabolic monitoring system.
C-CIT Sensors has released its new sensor product allowing users to monitor glucose and lactate in-situ and over weeks using one single-use sensor.
The measurement of critical process parameters (CPP) such as glucose and lactate is key to the understanding, development and control of bioprocesses of different kinds. Most labs today rely on frequent sampling and off-line analytics in order to follow the dynamics of a cell culture’s growth and metabolic status. These procedures are often manually conducted resulting in error-prone and risky data acquisition and processing. Many of them consume valuable and significant amounts of cell culture volume (and product) over the complete process time and require high upfront investment for instrumentation.
CITSens MeMo is an electrochemical, enzyme-based sensor with the capacity to be used in defined cell culture media and blood.
The continuous online/in-situ measurement of glucose and lactate as offered by CITSens MeMo adds value to cell line, media and process development projects within the cell bioresearch and biopharma community. The sensor system is unique and delivers real-time information on a culture’s growth behaviour and metabolic state at any given time. Data is being generated at a 20-second frequency and continuously sent to a database via wireless communication out of a closed incubator. Using a smartphone, a round-the-clock observation of your cell culture is here. Through straightforward OPC server connectivity, process control based on the online measured kinetics of glucose consumption and/or lactate generation has become reality.
The benefits are evident: Easy and fast learning about a cell culture’s metabolic behaviour under a given condition and straightforward process development at lowest investment and running cost, no risk of contamination, in-time information and automation, better science and engineering.
The single-use sensor comes as a standard product (a reactor probe containing a PG13.5 thread or as a flow cell sensor) or can be custom-manufactured as a cap sensor fitting any of the widely used brands of different cell culture vessels (T-flask, shake flask, roller bottle).
The product will be exhibited at booth 1732 during the BioProcess International Conference & Exhibition in the Hynes Convention Center, from 4-7 September 2018 and is available for beta testing as of 4 September 2018.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.